Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Misses Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) announced its quarterly earnings results on Friday. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03), RTT News reports. The company had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same period last year, the company earned $0.14 earnings per share. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Stock Up 3.5 %

Shares of NASDAQ AMRX traded up $0.29 during trading hours on Friday, hitting $8.67. The company had a trading volume of 2,898,126 shares, compared to its average volume of 1,319,121. The stock has a market capitalization of $2.69 billion, a P/E ratio of -12.75 and a beta of 1.10. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The firm’s 50 day moving average is $8.10 and its 200-day moving average is $8.32.

Insider Activity

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the sale, the director now owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 160,000 shares of company stock valued at $1,292,000. 26.56% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Finally, Piper Sandler upped their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $10.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.